1. Proteoglycans and glycosaminoglycans in misfolded proteins formation in Alzheimer's disease.
- Author
-
Wang P and Ding K
- Subjects
- Alzheimer Disease metabolism, Alzheimer Disease pathology, Amyloid beta-Peptides chemistry, Amyloid beta-Peptides metabolism, Clinical Trials as Topic, Glycosaminoglycans chemical synthesis, Heparin, Low-Molecular-Weight chemical synthesis, Heparin, Low-Molecular-Weight therapeutic use, Humans, Inositol chemical synthesis, Inositol therapeutic use, Phosphorylation, Propane analogs & derivatives, Propane chemical synthesis, Propane therapeutic use, Protein Aggregation, Pathological metabolism, Protein Aggregation, Pathological pathology, Protein Folding drug effects, Proteoglycans chemical synthesis, Sulfonic Acids chemical synthesis, Sulfonic Acids therapeutic use, Taurine analogs & derivatives, Taurine chemical synthesis, Taurine therapeutic use, tau Proteins chemistry, tau Proteins metabolism, Alzheimer Disease drug therapy, Amyloid beta-Peptides antagonists & inhibitors, Glycosaminoglycans therapeutic use, Protein Aggregation, Pathological prevention & control, Proteoglycans therapeutic use, tau Proteins antagonists & inhibitors
- Abstract
Misfolded protein amyloid-beta protein (Aβ) and tau protein are two high hallmarks of Alzheimer's disease (AD), representing significant targets in treating AD. Researches on mechanisms of the two proteins inducing neuron dysfunctions provide therapeutic strategies of AD, including inhibition of Aβ production and aggregation, acceleration of Aβ clearance as well as reduction of tau hyperphosphorylation. Proteoglycans (PGs) consist of a core protein and glycosaminoglycans (GAGs) chains, with enormous structural diversity due to variation in the core protein, the number of GAGs chains as well as extent and position of sulfation. Considerable evidences have indicated that PGs and GAGs play important roles in Aβ and tau processing. Numbers of GAGs and analogues have potential therapeutic function in AD. In this Review, we focus on the relationship of PGs and GAGs with misfolded proteins in AD and their potential therapeutic implications.
- Published
- 2014
- Full Text
- View/download PDF